Table 1.
Patient demographics.
| All Study Participants | Non-Evaluable | Evaluable | Gem/nab-P | Treatment Profile | FOLFIRINOX | ΔSMAD4 | ||
|---|---|---|---|---|---|---|---|---|
| Intermediate | Increase (+) | Decrease (−) | ||||||
| No. of patients (%) | 37 | 7 | 30 | 12 (40) | 7 (23) | 11 (37) | 14 | 7 |
| Mean age | 71.9 | 73.3 | 71.5 | 72.8 | 73.8 | 68.7 | 73.4 | 70.6 |
| Gender | ||||||||
| male | 21 | 6 | 15 | 5 | 3 | 7 | 6 | 4 |
| female | 16 | 1 | 15 | 7 | 4 | 4 | 8 | 3 |
| Stage | ||||||||
| III | 2 | 1 | 1 | 0 | 0 | 1 | 0 | 0 |
| IV | 35 | 6 | 29 | 12 | 7 | 10 | 14 | 7 |
| Performance status | ||||||||
| ECOG 0 | 3 | 0 | 3 | 1 | 0 | 2 | 2 | 0 |
| ECOG 1 | 24 | 3 | 21 | 7 | 7 | 7 | 7 | 6 |
| ECOG 2 | 10 | 4 | 6 | 4 | 0 | 2 | 5 | 1 |
Eastern Cooperative Oncology Group (ECOG), 5-fluorouracil (5-FU), leucovorin, irinotecan, oxaliplatin (FOLFIRINOX), gemcitabine with nab-paclitaxel (G/nab-P).